Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Comparative, Parallel Group Study to Assess the Immunogenicity of Lupin's Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer

NCT03511378 is registered in ClinicalTrials.gov with Lupin Ltd. as lead sponsor.

NCT NCT03511378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03511378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Comparative, Parallel Group Study to Assess the Immunogenicity of Lupin's Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer
Lead sponsor
Lupin Ltd.
Phase
Phase 4
Overall status
Completed
Start date
March 6, 2018
Completion date
January 9, 2019
Enrollment
138 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer